Please use this identifier to cite or link to this item:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia

AuthorsGonzález-Gascón y Marín, Isabel; Hernández-Sánchez, María; Rodríguez-Vicente, Ana Eugenia; Sanzo, Carmen; Aventín, Anna; Puiggros, Anna; Collado, Rosa; Heras, Cecilia; Muñoz-Novas, Carolina; Delgado, Julio; Ortega, Margarita; González, María-Teresa; Marugán, Isabel; Fuente, Ignacio de la; Recio, Isabel; Bosch, Francesc; Espinet, Blanca; González, Marcos CSIC ORCID ; Hernández, Jesús M. CSIC ORCID ; Hernández, José Ángel
KeywordsChronic lymphocytic leukemia
Issue Date2016
PublisherJohn Wiley & Sons
CitationHematological Oncology 34(2): 84-92 (2016)
AbstractThe prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129 months. One hundred seventy-four patients (60.2%) presented +12 in <60% of cells. TTFT and OS for this subgroup were longer than for the subgroup with +12 in ≥60% of cells, with a median TTFT of 49 months (CI95%, 39–58) vs 30 months (CI95%, 22–38) (P = 0.001); and a median OS of 159 months (CI95%, 119–182), vs 96 months (CI95%, 58–134) (P = 0.015). Other factors associated with a shorter TTFT were: Binet stage, B symptoms, lymphadenopathy, splenomegaly, high lymphocyte count, 11q-, high βmicroglobulin, and high LDH. In the multivariate analysis, clinical stage, +12 in ≥60% of cells, high lymphocyte count, B symptoms, and 11q- in addition, resulted of significance in predicting shorter TTFT. Significant variables for OS were: Binet stage, lymphadenopathy, splenomegaly, high LDH, high βmicroglobulin, 11q-, and CD38. In the multivariate analysis, only Binet stage, 11q-, and high β2microglobulin significantly predicted shorter OS. CLL with +12 entails a heterogeneous group with intermediate prognosis. However, a high proportion of cells carrying +12 separates a subgroup of patients with poor outcome.
DescriptionOn behalf of Grupo Español de Leucemia Linfática Crónica (GELLC), Grupo Cooperativo Español de Citogenética Hematológica (GCECGH).
Identifiersdoi: 10.1002/hon.2196
e-issn: 1099-1069
issn: 0278-0232
Appears in Collections:(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

PubMed Central

checked on Nov 23, 2021


checked on Nov 30, 2021


checked on Dec 1, 2021

Google ScholarTM




Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.